Changes in Beneficial Ownership · 4
Kodiak Sciences Inc
KODNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-07022026_090725.xml
Filing details
- Report period
- 2026-06-30
- Issuer
- Kodiak Sciences Inc.
- Issuer CIK
- 0001468748
- Trading symbol
- KOD
Reporting owner 1
- Name
- Yang Taiyin
- Reporting owner CIK
- 0001334505
- Relationship
- Director
- Address
- 1250 PAGE MILL ROAD, PALO ALTO, CA, 94304
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 38.96 | 2026-06-30 | A · Form 4 | 17,731 | A | 0 | [F1] | 2036-06-29 | Common Stock | 17,731 | 17,731 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2027 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date.↩ 1
Signature 1
- Signed
- /s/ David Peinsipp, Attorney-in-Fact for Taiyin Yang
- Date
- 2026-07-02
Company context
Kodiak Sciences (Nasdaq: KOD) is a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics. We are focused on bringing new science to the design and manufacture of next-generation retinal medicines to prevent and treat the leading causes of blindness globally. We are developing a portfolio of three late-stage clinical programs. Zenkuda (tarcocimab tedromer) has a BLA-ready profile in wet AMD, diabetic retinopathy, and retinal vein occlusion. KSI-501 is being evaluated in wet AMD and diabetic macular edema. Zenkuda and KSI-501 target the $15 billion anti-VEGF market across retinal vascular diseases. KSI-101 is a bispecific protein being explored in two BLA-facing Phase 3 studies in Macular Edema Secondary to Inflammation (MESI). Topline data for Pivotal Analysis 1 (PEAK) are expected in December 2026 and Pivotal Analysis 2 (PEAK+PINNACLE) in 2Q 2027.